作为治疗目标的DOT1L:对表观遗传调节和癌症治疗的洞察
Hee-Joo Choi1, Minh Tuan Nguyen2, Boram Kim2
1Department of Pathology, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea.
Biomolecules & therapeutics
|October 31, 2025
概括
端粒沉默1-Like (DOT1L) 的破坏者是癌症中的关键表观遗传调节剂. 用抑制剂向DOT1L显示出治疗各种癌症的前景,包括白血病和固体瘤.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 破坏端粒沉默1-Like (DOT1L) 是唯一的H3K79甲基转移酶,对基因调节至关重要.
- DOT1L失调与血液和固体瘤有关.
- 它影响了关键的癌症过程,如MLL重新安排的白血病,血管新生和转移.
研究的目的:
- 审查最近关于DOT1L在癌症发展中的作用的发现.
- 探索DOT1L作为瘤学中的治疗点.
主要方法:
- 在癌症中对DOT1L进行临床前和临床研究的文献综述.
- 分析DOT1L的表观遗传机制及其对瘤发生的影响.
主要成果:
- 在MLL白血病中,DOT1L维持异常基因表达,支持白血病干细胞.
- 在固体瘤中,DOT1L会影响上皮质-介质酶过渡,血管生成和细胞循环.
- 像EPZ-5676这样的DOT1L抑制剂显示出治疗潜力.
结论:
- DOT1L是一种多功能表观遗传点,用于各种癌症.
- 准DOT1L为精确瘤学提供了一个有前途的战略.
更多相关视频
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
3.0K
10:41An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
10.8K
相关概念视频
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Epigenetic Regulation
33.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
